Skip to main content
SpringerLink
Log in

Pathogenesis of Type 2 Diabetes

  • Chapter
  • First Online:
Atlas of Diabetes

Abstract

Type 2 diabetes is one of the most common chronic diseases. In the USA, it affects about 8% of the population. In addition to 18 million people with diagnosed diabetes, 6 million have undiagnosed diabetes and 57 million have prediabetes [i.e., impaired fasting glucose (IFG) or impaired glucose tolerance (IGT)] [ 1 ]. Phenotypically, more than 90% of people with diabetes mellitus have type 2 diabetes. This disorder, however, is extremely heterogeneous (see Fig. 7.1).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 159.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. American Diabetes Association: Total prevalence of diabetes and pre-diabetes, 2007. Available at http://diabetes.org. Accessed September 2009.

  2. Bogardus C, Lillioja S, Bennett P: Pathogenesis of NIDDM in Pima Indians. Diabetes Care1991, 14:685–690.

    Google Scholar 

  3. Cheung BM, Ong KL, Cherny SS, et al.: Diabetes prevalence and therapeutic target achievement in the United States, 1999 to 2006. Am J Med2009, 122:443–453.

    Google Scholar 

  4. Weyer C, Tataranni PA, Bogardus C, Pratley R: Insulin resistance and insulin secretory dysfunction are independent predictors of worsening of glucose tolerance during each stage of type 2 diabetes development. Diabetes Care2000, 24:89–94.

    Google Scholar 

  5. Weyer C, Bogardus C, Mott D, Pratley R: The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest1999, 104:787–794.

    Google Scholar 

  6. Kahn S: The importance of ß-cell failure in the development and progression of type 2 diabetes. J Clin Endocrinol Metab2001, 86:4047–4058.

    Google Scholar 

  7. Pratley R, Weyer C: The role of impaired early insulin secretion in the pathogenesis of type II diabetes mellitus. Diabetologia2001, 44:929–945.

    Google Scholar 

  8. Hamman R: Genetic and environmental determinants of noninsulin dependent diabetes mellitus (NIDDM). Diabetes Metab Rev1992, 8:287–338.

    Google Scholar 

  9. Stefan N, Fritsche A, Haring H, Stumvoll M: Effect of experimental elevation of free fatty acids on insulin secretion and insulin sensitivity in healthy carriers of the Pro12Ala polymorphism of the peroxisome proliferator-activated receptor-gamma2 gene. Diabetes2001, 50:1143–1148.

    Google Scholar 

  10. Horikawa Y, Oda N, Cox N, et al.: Genetic variation in the gene encoding calpain-10 is associated with type 2 diabetes mellitus. Nat Genet2000, 26:163–175.

    Google Scholar 

  11. Gloyn AL, Weedon MN, Owen KR, et al.: Large-scale association studies of variants in genes encoding the pancreatic beta-cell KATP channel subunits Kir6.2 (KCNJ11) and SUR1 (ABCC8) confirm that the KCNJ11 E23K variant is associated with type 2 diabetes. Diabetes2003, 52:568–572.

    Google Scholar 

  12. Florez JC, Jablonski KA, Kahn SE, et al.: Type 2 diabetes-associated missense polymorphisms KCNJ11 E23K and ABCC8 A1369S influence progression to diabetes and response to interventions in the Diabetes Prevention Program. Diabetes2007, 56:531–536.

    Google Scholar 

  13. Florez JC, Jablonski KA, Bayley N, et al.: TCF7L2 polymorphisms and progression to diabetes in the Diabetes Prevention Program. N Engl J Med2006, 355:241–250.

    Google Scholar 

  14. Zhang C, Qi L, Hunter DJ, et al.: Variant of transcription factor 7-like 2 (TCF7L2) gene and the risk of type 2 diabetes in large cohorts of U.S. women and men. Diabetes2006, 55:2645–2648.

    Google Scholar 

  15. Grant SF, Thorleifsson G, Reynisdottir I, et al.: Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes. Nat Genet2006, 38:320–323.

    Google Scholar 

  16. Yi F, Brubaker PL, Jin T: TCF-4 mediates cell type-specific regulation of proglucagon gene expression by beta-catenin and glycogen synthase kinase-3beta. J Biol Chem2005, 280:1457–1464.

    Google Scholar 

  17. Saltiel A, Kahn C: Insulin signalling and the regulation of glucose and lipid metabolism. Nature2001, 414:799–806.

    Google Scholar 

  18. Gloyn A: The genetics of diabetes: a progress report. Practical Diabetes Int2001, 18:246–250.

    Google Scholar 

  19. Shaw J, Purdie D, Neil H, et al.: The relative risks of hyperglycemia, obesity and dyslipidemia in relatives of patients with type II diabetes mellitus. Diabetologia1999, 42:24–27.

    Google Scholar 

  20. Shatten B, Smith G, Kuller L, Neation J: Risk factors for the development of type 2 diabetes among men enrolled in the usual care group of the multiple risk factor intervention trial. Diabetes1993, 16:1331–1338.

    Google Scholar 

  21. Gerich J, Van Haeften T: Insulin resistance versus impaired insulin secretion as the genetic basis for type 2 diabetes. Curr Opin Endocrinol Diabetes1998, 5:144–148.

    Google Scholar 

  22. Pimenta W, Kortytkowski M, Mitrakou A, et al.: Pancreatic beta-cell dysfunction as the primary genetic lesion in NIDDM. Evidence from studies in normal glucose-tolerant individuals with a first-degree NIDDM relative. JAMA1995, 273:1855–1861.

    Google Scholar 

  23. Vaag A, Alford F, Beck-Nielsen H: Intracellular glucose and fat metabolism in identical twins discordant for non-insulin-dependent diabetes mellitus (NIDDM): acquired versus genetic metabolic defects. Diabetic Med1996, 13:806–815.

    Google Scholar 

  24. Cerasi E, Luft R: Insulin response to glucose infusion in diabetic and nondiabetic monozygotic twin pairs: genetic control of insulin response. Acta Endocrinol1967, 55:330–345.

    Google Scholar 

  25. Barnett A, Spiliopoulos A, Pyke D, et al.: Metabolic studies in unaffected co-twins of noninsulin dependent diabetics. Br Med J1981, 282:1656–1658.

    Google Scholar 

  26. Pyke D, Taylor K: Glucose tolerance and serum insulin in unaffected identical twins of diabetics. Br Med J1967, 4:21–22.

    Google Scholar 

  27. Hu F, Manson J, Stampfer M, et al.: Diet, lifestyle, and the risk of type 2 diabetes mellitus in women. N Engl J Med2001, 345:790–797.

    Google Scholar 

  28. Choi B, Shi F: Risk factors for diabetes mellitus by age and sex: results of the national population health survey. Diabetologia2001, 44:1221–1231.

    Google Scholar 

  29. Marshall J, Hoag S, Shetterly S, Hammon R: Dietary fat predicts conversion of impaired glucose tolerance to NIDDM. Diabetes Care1994, 17:50–56.

    Google Scholar 

  30. Wei M, Schweitner H, Blair S: The association between physical activity, physical fitness and type 2 diabetes mellitus. Compr Ther2000, 26:176–182.

    Google Scholar 

  31. Wannamethee S, Shaper A, Perry I: Smoking as a modifiable risk factor for type 2 diabetes in middle aged men. Diabetes Care2001, 24:1590–1595.

    Google Scholar 

  32. Rich-Edwards J, Colditz G, Stampfer M, et al.: Birthweight and the risk for type 2 diabetes mellitus in adult women. Ann Intern Med1999, 130:278–284.

    Google Scholar 

  33. Eriksson J, Lindstrom J, Tuomilehto J: Potential for prevention of type 2 diabetes. Br Med Bull2001, 60:183–199.

    Google Scholar 

  34. Knowler W, Barrett-Connor E, Fowler S, et al.: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med2002, 346:393–403.

    Google Scholar 

  35. Tuomilehto J, Lindström J, Eriksson J, et al.: Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med2001, 344:1343–1350.

    Google Scholar 

  36. Pan X-R, Li G-W, Hu Y-H, et al.: Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance: the Da Qing IGT and Diabetes Study. Diabetes Care1997, 20:537–544.

    Google Scholar 

  37. Eriksson K, Lindgarde F: Prevention of type 2 (noninsulin dependent) diabetes mellitus by diet and exercise. Diabetologia1991, 34:891–898.

    Google Scholar 

  38. Wenying Y, Lixiang L, Jinwu Q, et al.: The preventive effect of acarbose and metformin on the progression to diabetes mellitus in the IGT population: a 3-year multicenter prospective study. Chin J Endocrinol Metab2001, 17:131–136.

    Google Scholar 

  39. Chiasson J, Josse R, Gomis R, et al.: Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet2002, 359:2072–2077.

    Google Scholar 

  40. Buchanan TA, Xiang AH, Peters RK, et al.: Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women. Diabetes2002, 51:2796–2803.

    Google Scholar 

  41. Torgerson JS, Hauptman J, Boldrin MN, Sjostrom L: XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care2004, 27:155–161.

    Google Scholar 

  42. Vetter ML, Cardillo S, Rickels MR, Iqbal N: Narrative review: effect of bariatric surgery on type 2 diabetes mellitus. Ann Intern Med2009, 150:94–103.

    Google Scholar 

  43. Buchwald H, Avidor Y, Braunwald E, et al.: Bariatric surgery: a systematic review and meta-analysis. JAMA2004, 292:1724–1737.

    Google Scholar 

  44. Pories WJ, Swanson MS, MacDonald KG, et al.: Who would have thought it? An operation proves to be the most effective therapy for adult-onset diabetes mellitus. Ann Surg1995, 222:339–350.

    Google Scholar 

  45. Cummings DE, Overduin J: Gastrointestinal regulation of food intake. J Clin Invest2007, 117:13–23.

    Google Scholar 

  46. Kageyama H, Funahashi H, Hirayama M, et al.: Morphological analysis of ghrelin and its receptor distribution in the rat pancreas. Regul Pept2005, 126:67–71.

    Google Scholar 

  47. Ballantyne GH: Peptide YY(1–36) and peptide YY(3–36): Part I. Distribution, release and actions. Obes Surg2006, 16:651–658.

    Google Scholar 

  48. Clements RH, Gonzalez QH, Long CI, et al.: Hormonal changes after Roux-en Y gastric bypass for morbid obesity and the control of type-II diabetes mellitus. Am Surg2004, 70:1–4.

    Google Scholar 

  49. Laferrere B, Teixeira J, McGinty J, et al.: Effect of weight loss by gastric bypass surgery versus hypocaloric diet on glucose and incretin levels in patients with type 2 diabetes. J Clin Endocrinol Metab2008, 93:2479–2485.

    Google Scholar 

  50. Korner J, Bessler M, Inabnet W, et al.: Exaggerated glucagon-like peptide-1 and blunted glucose-dependent insulinotropic peptide secretion are associated with Roux-en-Y gastric bypass but not adjustable gastric banding. Surg Obes Relat Dis2007, 3:597–601.

    Google Scholar 

  51. le Roux CW, Welbourn R, Werling M, et al.: Gut hormones as mediators of appetite and weight loss after Roux-en-Y gastric bypass. Ann Surg2007, 246:780–785.

    Google Scholar 

  52. Morinigo R, Moize V, Musri M, et al.: Glucagon-like peptide-1, peptide YY, hunger, and satiety after gastric bypass surgery in morbidly obese subjects. J Clin Endocrinol Metab2006, 91:1735–1740.

    Google Scholar 

  53. Cummings DE, Weigle DS, Frayo RS, et al.: Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N Engl J Med2002, 346:1623–1630.

    Google Scholar 

  54. Faraj M, Havel PJ, Phelis S, et al.: Plasma acylation-stimulating protein, adiponectin, leptin, and ghrelin before and after weight loss induced by gastric bypass surgery in morbidly obese subjects. J Clin Endocrinol Metab2003, 88:1594–1602.

    Google Scholar 

  55. Holdstock C, Engstrom BE, Ohrvall M, et al.: Ghrelin and adipose tissue regulatory peptides: effect of gastric bypass surgery in obese humans. J Clin Endocrinol Metab2003, 88:3177–3183.

    Google Scholar 

  56. Cummings DE, Overduin J, Foster-Schubert KE, Carlson MJ: Role of the bypassed proximal intestine in the anti-diabetic effects of bariatric surgery. Surg Obes Relat Dis2007, 3:109–115.

    Google Scholar 

  57. Rubino F: Is type 2 diabetes an operable intestinal disease? A provocative yet reasonable hypothesis. Diabetes Care2008, 31(Suppl 2):S290–S296.

    Google Scholar 

  58. Porte D Jr, Kahn S: Beta-cell dysfunction and failure in type 2 diabetes: potential mechanisms. Diabetes2001, 50(Suppl 1):S160–S163.

    Google Scholar 

  59. Carey D, Jenkins A, Campbell L, et al.: Abdominal fat and insulin resistance in normal and overweight women: direct measurements reveal a strong relationship in subjects at both low and high risk of NIDDM. Diabetes1996, 45:633–638.

    Google Scholar 

  60. Banerji M, Chaiken R, Gordon D, et al.: Does intra-abdominal ­adipose tissue in black men determine whether NIDDM is insulin-resistant or insulin-sensitive? Diabetes1995, 44:141–146.

    Google Scholar 

  61. Byrne M, Sturgis J, Sobel R, Polonsky K: Elevated plasma glucose 2h postchallenge predicts defects in B-cell function. Am J Physiol1996, 270:E572–E579.

    Google Scholar 

  62. Nesher R, Casa Della L, Litvin Y, et al.: Insulin deficiency and insulin resistance in type II (noninsulin dependent) diabetes: quantitative contributions of pancreatic and peripheral responses to glucose homeostasis. Eur J Clin Invest1987, 17:266–274.

    Google Scholar 

  63. Campbell P, Mandarino L, Gerich J: Quantification of the relative impairment in actions of insulin on hepatic glucose production and peripheral glucose uptake in non-insulin-dependent diabetes mellitus. Metabolism1988, 37:15–21.

    Google Scholar 

  64. Kalant N, Leibovici D, Fukushima N, et al.: Insulin responsiveness of superficial forearm tissues in type 2 (noninsulin-dependent) diabetes. Diabetologia1982, 22:239–244.

    Google Scholar 

  65. Bonora E, Bonadonna R, DelPrato S, et al.: In vivo glucose metabolism in obese and type II diabetic subjects with or without hypertension. Diabetes1993, 42:764–772.

    Google Scholar 

  66. Nosadini R, Solini A, Velussi M, et al.: Impaired insulin-induced glucose uptake by extrahepatic tissue is hallmark of NIDDM patients who have or will develop hypertension and microalbuminuria. Diabetes1994, 43:491–499.

    Google Scholar 

  67. Groop L, Ekstrand A, Forsblom C, et al.: Insulin resistance, hypertension and microalbuminuria in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia1993, 36:642–647.

    Google Scholar 

  68. Gerich J: The genetic basis of type 2 diabetes mellitus: Impaired insulin secretion versus impaired insulin sensitivity. Endocr Rev1998, 19:491–503.

    Google Scholar 

  69. Dohm GL, Tapscott E, Pories W, et al.: An in vitro human muscle preparation suitable for metabolic studies. Decreased insulin stimulation of glucose transport in muscle from morbidly obese and diabetic subjects. J Clin Invest1988, 82:486–494.

    Google Scholar 

  70. Boden G: Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes1997, 46:3–10.

    Google Scholar 

  71. Hotamisligil G, Spiegelman B: Tumor necrosis factor alpha: a key component of the obesity-diabetes link. Diabetes1994, 43:1271–1278.

    Google Scholar 

  72. Steppan C, Bailey S, Bhat S, et al.: The hormone resistin links obesity to diabetes. Nature2001, 409:307–312.

    Google Scholar 

  73. Ahima R, Flier J: Leptin. Annu Rev Physiol2000, 62:413–437.

    Google Scholar 

  74. Ahima R, Flier J: Adipose tissue as an endocrine organ. Trends Endocrinol Metab2000, 11:327–332.

    Google Scholar 

  75. Kelley D, Goodposter B: Skeletal muscle triglyceride: an aspect of regional adiposity and insulin resistance. Diabetes Care2001, 24:933–941.

    Google Scholar 

  76. Virkamaki A, Korsheninnikova E, Seppala-Lindroos A, et al.: Intramyocellular lipid is associated with resistance to in vivo insulin actions on glucose uptake, antilipolysis, and early insulin signaling pathways in human skeletal muscle. Diabetes2001, 50:2337–2343.

    Google Scholar 

  77. Mitrakou A, Kelley D, Veneman T, et al.: Contribution of abnormal muscle and liver glucose metabolism in postprandial hyperglycemia in noninsulin-dependent diabetes mellitus. Diabetes1990, 39:1381–1390.

    Google Scholar 

  78. Dinneen S, Gerich J, Rizza R: Carbohydrate metabolism in noninsulin-dependent diabetes mellitus. N Engl J Med1992, 327:707–713.

    Google Scholar 

  79. Woerle HJ, Szoke E, Meyer C, et al.: Mechanisms for abnormal postprandial glucose metabolism in type 2 diabetes. Am J Physiol Endocrinol Metab2006, 290:E67–E77.

    Google Scholar 

  80. Perseghin G, Petersen K, Shulman GI: Cellular mechanism of insulin resistance: potential links with inflammation. Int J Obes Relat Metab Disord2003, 27 Suppl 3:S6–11.

    Google Scholar 

  81. Petersen KF, Dufour S, Befroy D, et al.: Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes. N Engl J Med2004, 350:664–671.

    Google Scholar 

  82. Patel A, MacMahon S, Chalmers J, et al.: Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med2008, 358:2560–2572.

    Google Scholar 

  83. DCCT Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin dependent diabetes mellitus. N Engl J Med1993, 329:977–986.

    Google Scholar 

  84. UK Prospective Diabetes Study (UKPDS) Group: Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet1998, 352:854–865.

    Google Scholar 

  85. Reichard P, Pihl M, Rosenqvist U, Sule J: Complications in IDDM are caused by elevated blood glucose level: The Stockholm Diabetes Intervention Study (SDIS) at 10-year follow up. Diabetologia1996, 39:1483–1488.

    Google Scholar 

  86. Gerstein HC, Miller ME, Byington RP, et al.: Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med2008, 358:2545–2559.

    Google Scholar 

  87. Abraira C, Duckworth WC, Moritz T: Glycaemic separation and risk factor control in the Veterans Affairs Diabetes Trial: an interim report. Diabetes Obes Metab2009, 11:150–156.

    Google Scholar 

  88. UK Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet1998, 352:837–853.

    Google Scholar 

  89. Holman RR, Paul SK, Bethel MA, et al.: 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med2008, 359:1577–1589.

    Google Scholar 

  90. DCCT Research Group: Effect of intensive diabetes management on macrovascular events and risk factors in the Diabetes Control and Complications Trial. Am J Cardiol1995, 75:894–903.

    Google Scholar 

  91. Nathan DM, Cleary PA, Backlund JY, et al.: Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med2005, 353:2643–2653.

    Google Scholar 

  92. Gerich JE: Clinical significance, pathogenesis, and management of postprandial hyperglycemia. Arch Intern Med2003, 163:1306–1316.

    Google Scholar 

  93. Chiasson JL, Josse RG, Gomis R, et al.: Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA2003, 290:486–494.

    Google Scholar 

  94. Rodbard HW, Blonde L, Braithwaite SS, et al.: American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract2007, 13(Suppl 1):1–68.

    Google Scholar 

  95. Nathan DM, Buse JB, Davidson MB, et al.: Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care2006, 29:1963–1972.

    Google Scholar 

  96. Woerle HJ, Pimenta W, Meyer C, et al.: Diagnostic and therapeutic implications of relationships between fasting, 2 hour postchallenge plasma glucose and HbA1cvalues. Arch Intern Med2004, 164:1627–1632.

    Google Scholar 

  97. Lebovitz H: Insulin secretogogues: old and new. Diab Rev1999, 7:139–153.

    Google Scholar 

  98. Langtry H, Balfour J: Glimepiride. A review of its use in the management of type 2 diabetes mellitus. Drugs1998, 55:563–584.

    Google Scholar 

  99. Dunn C, Faulds D: Nateglinide. Drugs2000, 60:607–615.

    Google Scholar 

  100. Lee Y, Hirose H, Ohneda M, et al.: Beta-cell lipotoxicity in the pathogenesis of non-insulin-dependent diabetes mellitus of obese rats: impairment in adipocyte-beta-cell relationships. Proc Natl Acad Sci U S A1994, 91:10878–10882.

    Google Scholar 

  101. Mudaliar S, Henry R: New oral therapies for type 2 diabetes mellitus: the glitazones or insulin sensitizers. Annu Rev Med2001, 52:239–257.

    Google Scholar 

  102. Inzucchi S, Maggs D, Spollett G, et al.: Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N Engl J Med1998, 338:867–872.

    Google Scholar 

  103. Campbell L, Baker D, Campbell RK: Miglitol: assessment of its role in the treatment of patients with diabetes mellitus. Ann Pharmacother2000, 34:1291–1301.

    Google Scholar 

  104. Bolli G, Di Marchi R, Park G, et al.: Insulin analogues and their potential in the management of diabetes mellitus. Diabetologia1999, 42:1151–1167.

    Google Scholar 

  105. Lepore M, Pampanelli S, Fanelli C, et al.: Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes2000, 49:2142–2148.

    Google Scholar 

  106. Abraira C, Henderson W, Colwell J, et al.: Response to intensive therapy steps and glipizide dose in combination with insulin in type 2 diabetes. Diabetes Care1998, 21:574–579.

    Google Scholar 

  107. Turner R, Cull C, Frighi V, Holman R: Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus. Progressive requirement for multiple therapies (UKPDS 49). JAMA1999, 281:2005–2012.

    Google Scholar 

  108. Siegel E, Mayer G, Nauck M, Creutzfeldt W: [Factitious hypoglycemia caused by taking a sulfonylurea drug] [German]. Dtsch Med Wochenschr1987, 112:1575–1579.

    Google Scholar 

  109. Wroblewski M, Gottsater A, Lindgarde F, et al.: Gender, autoantibodies, and obesity in newly diagnosed diabetic patients aged 40–75 years. Diabetes Care1998, 21:250–255.

    Google Scholar 

  110. Bell G, Polonsky K: Diabetes mellitus and genetically programmed defects in beta-cell function. Nature2001, 414:788–791.

    Google Scholar 

  111. Diabetes in America, edn 2. Bethesda, MD: National Institutes of Health; 1995.

    Google Scholar 

  112. Kahn C: Insulin action, diabetogenes, and the cause of type II diabetes. Diabetes1994, 43:1066–1084.

    Google Scholar 

  113. Beals JK: Pioglitazone reduces conversion from impaired glucose tolerance to type 2 diabetes. Presented at the American Diabetes Association 68th Scientific Sessions: Late Breaking Clinical Studies. San Francisco, CA; June 9, 2008. Medscape Medical News 2008. Accessible at http://www.medscape.com/viewarticle/575860. Accessed September 3, 2009.

  114. Gerstein HC, Yusuf S, Bosch J, et al.: Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet2006, 368:1096–1105.

    Google Scholar 

  115. Kahn S: The importance of the ß-cell in the pathogenesis of type 2 diabetes mellitus. Am J Med2000, 108(Suppl 6A):2S–8S.

    Google Scholar 

  116. Thorens B, Wu Y, Leahy J, Weir G: The loss of GLUT2 expression by glucose-unresponsive beta cells of db/db mice is reversible and is induced by the diabetic environment. J Clin Invest1992, 90:77–85.

    Google Scholar 

  117. Caro J, Sinha M, Raju SM, et al.: Insulin receptor kinase in human skeletal muscle from obese subjects with and without noninsulin dependent diabetes. J Clin Invest1987, 79:1330–1337.

    Google Scholar 

  118. Bak J, Moller N, Schmitz O, et al.: In vivo action and muscle glycogen synthase activity in type II (noninsulin dependent) diabetes mellitus: effects of diet treatment. Diabetologia1992, 35:777–784.

    Google Scholar 

  119. McGarry J, Dobbins R: Fatty acids, lipotoxicity and insulin secretion. Diabetologia1999, 42:128–138.

    Google Scholar 

  120. Unger R, Zhou Y: Lipotoxicity of beta-cells in obesity and in other causes of fatty acid spillover. Diabetes2001, 50(Suppl 1):S118–S121.

    Google Scholar 

  121. Randle P, Priestman D, Mistry S, Halsall A: Glucose fatty acid interactions and the regulation of glucose disposal. J Cell Biochem1994, 55S:1–11.

    Google Scholar 

  122. Shulman G: Cellular mechanisms of insulin resistance. J Clin Invest2000, 106:171–176.

    Google Scholar 

  123. Garvey W, Huecksteadt T, Matthaei S, Olefsky J: Role of glucose transporters in the cellular insulin resistance of type II noninsulin-dependent diabetes mellitus. J Clin Invest1988, 81:1528–1536.

    Google Scholar 

  124. Kelley D, Mintun M, Watkins S, et al.: The effect of non-insulin-dependent diabetes mellitus and obesity on glucose transport and phosphorylation in skeletal muscle. J Clin Invest1996, 97:2705–2713.

    Google Scholar 

  125. Cline G, Petersen K, Krssak M, et al.: Impaired glucose transport as a cause of decreased insulin-stimulated muscle glycogen synthesis in type 2 diabetes. N Engl J Med1999, 341:240–246.

    Google Scholar 

  126. Butler AE, Janson J, Bonner-Weir S, et al.: Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes2003, 52:102–110.

    Google Scholar 

  127. Yoon KH, Ko SH, Cho JH, et al.: Selective beta-cell loss and alpha-cell expansion in patients with type 2 diabetes mellitus in Korea. J Clin Endocrinol Metab2003, 88:2300–2308.

    Google Scholar 

  128. Guiot Y, Sempoux C, Moulin P, Rahier J: No decrease of the beta-cell mass in type 2 diabetic patients. Diabetes2001, 50(Suppl 1):S188.

    Google Scholar 

  129. Stefan Y, Orci L, Malaisse-Lagae F, et al.: Quantitation of endocrine cell content in the pancreas of nondiabetic and diabetic humans. Diabetes1982, 31:694–700.

    Google Scholar 

  130. Sakuraba H, Mizukami H, Yagihashi N, et al.: Reduced beta-cell mass and expression of oxidative stress-related DNA damage in the islet of Japanese Type II diabetic patients. Diabetologia2002, 45:85–96.

    Google Scholar 

  131. Clark A, Wells C, Buley I, et al.: Islet amyloid, increased alpha-cells, reduced beta-cells and exocrine fibrosis: quantitative changes in the pancreas in type 2 diabetes. Diabetes Res1988, 9:151–159.

    Google Scholar 

  132. Kloppel G, Lohr M, Habich K, et al.: Islet pathology and the pathogenesis of type 1 and type 2 diabetes mellitus revisited. Surv Synth Pathol Res1985, 4:110–125.

    Google Scholar 

  133. Gepts W: Contribution to the morphological study of the islands of Langerhans in diabetes; study of the quantitative variations of the different insular constituents. Ann Soc R Sci Med Nat Brux1957, 10:5–108.

    Google Scholar 

  134. Saito K, Yaginuma N, Takahashi T: Differential volumetry of A, B, and D cells in the pancreatic islets of diabetic and nondiabetic subjects. Tohoku J Exp Med1979, 129:273–283.

    Google Scholar 

  135. MacLean N, Ogilvie RF: Quantitative estimation of the pancreatic islet tissue in diabetic subjects. Diabetes1955, 4:367–376.

    Google Scholar 

  136. Westermark P, Wilander E: The influence of amyloid deposits on the islet volume in maturity onset diabetes mellitus. Diabetologia1978, 15:417–421.

    Google Scholar 

  137. Rahier J, Guiot Y, Goebbels RM, et al.: Pancreatic beta-cell mass in European subjects with type 2 diabetes. Diabetes Obes Metab2008, 10(Suppl 4):32–42.

    Google Scholar 

  138. Deng S, Vatamaniuk M, Huang X, et al.: Structural and functional abnormalities in the islets isolated from type 2 diabetic subjects. Diabetes2004, 53:624–632.

    Google Scholar 

  139. Hales C, Barker D, Clark P, et al.: Fetal and infant growth and impaired glucose tolerance at age 64. BMJ1991, 303:1019–1022.

    Google Scholar 

  140. Dahri S, Snoeck A, Reusens-Billen B, et al.: Islet function in offspring of mothers on low-protein diet during gestation. Diabetes1991, 40(Suppl 2):115–120.

    Google Scholar 

  141. Moran A, Zhang HJ, Olson LK, et al.: Differentiation of glucose toxicity from beta cell exhaustion during the evolution of defective insulin gene expression in the pancreatic islet cell line, HIT-T15. J Clin Invest1997, 99:534–539.

    Google Scholar 

  142. Olson LK, Redmon JB, Towle HC, Robertson RP: Chronic exposure of HIT cells to high glucose concentrations paradoxically decreases insulin gene transcription and alters binding of insulin gene regulatory protein. J Clin Invest1993, 92:514–519.

    Google Scholar 

  143. Lu M, Seufert J, Habener JF: Pancreatic beta-cell-specific repression of insulin gene transcription by CCAAT/enhancer-binding protein beta. Inhibitory interactions with basic helix-loop-helix transcription factor E47. J Biol Chem1997, 272:28349–28359.

    Google Scholar 

  144. Jonas JC, Sharma A, Hasenkamp W, et al.: Chronic hyperglycemia triggers loss of pancreatic beta cell differentiation in an animal model of diabetes. J Biol Chem1999, 274:14112–14121.

    Google Scholar 

  145. Tanaka Y, Gleason CE, Tran PO, et al.: Prevention of glucose toxicity in HIT-T15 cells and Zucker diabetic fatty rats by antioxidants. Proc Natl Acad Sci U S A1999, 96:10857–10862.

    Google Scholar 

  146. Tajiri Y, Moller C, Grill V: Long-term effects of aminoguanidine on insulin release and biosynthesis: evidence that the formation of advanced glycosylation end products inhibits B cell function. Endocrinology1997, 138:273–280.

    Google Scholar 

  147. Cnop M, Hannaert JC, Hoorens A, et al.: Inverse relationship between cytotoxicity of free fatty acids in pancreatic islet cells and cellular triglyceride accumulation. Diabetes2001, 50:1771–1777.

    Google Scholar 

  148. Maedler K, Spinas GA, Dyntar D, et al.: Distinct effects of saturated and monounsaturated fatty acids on beta-cell turnover and function. Diabetes2001, 50:69–76.

    Google Scholar 

  149. Gremlich S, Bonny C, Waeber G, Thorens B: Fatty acids decrease IDX-1 expression in rat pancreatic islets and reduce GLUT2, glucokinase, insulin, and somatostatin levels. J Biol Chem1997, 272:30261–30269.

    Google Scholar 

  150. Farney AC, Xenos E, Sutherland DE, et al.: Inhibition of pancreatic islet beta cell function by tumor necrosis factor is blocked by a soluble tumor necrosis factor receptor. Transplant Proc1993, 25:865–866.

    Google Scholar 

  151. Bolaffi JL, Rodd GG, Wang J, Grodsky GM: Interrelationship of changes in islet nicotine adenine nucleotide, insulin secretion, and cell viability induced by interleukin-1 beta. Endocrinology1994, 134:537–542.

    Google Scholar 

  152. Campbell IL, Oxbrow L, Harrison LC: Interferon-gamma: pleiotropic effects on a rat pancreatic beta cell line. Mol Cell Endocrinol1987, 52:161–167.

    Google Scholar 

  153. Janson J, Ashley R, Harrison D, et al.: The mechanism of islet amyloid polypeptide toxicity is membrane disruption by intermediate-sized toxic amyloid particles. Diabetes1999, 48:491–498.

    Google Scholar 

  154. Clark A, Nilsson MR: Islet amyloid: a complication of islet dysfunction or an aetiological factor in Type 2 diabetes? Diabetologia2004, 47:157–169.

    Google Scholar 

  155. Mitrakou A, Kelley D, Mokan M, et al.: Role of reduced suppression of glucose production and diminished early insulin release in impaired glucose tolerance. N Engl J Med1992, 326:22–29.

    Google Scholar 

  156. Gerich J: Metabolic abnormalities in impaired glucose tolerance. Metabolism1997, 46(Suppl 1):40–43.

    Google Scholar 

  157. Van Haeften T, Pimenta W, Mitrakou A, et al.: Relative contributions of β-cell function and tissue insulin sensitivity to fasting and postglucose-load glycemia. Metabolism2000, 49:1318–1325.

    Google Scholar 

  158. DeFronzo R: The triumvirate: B-cell, muscle, and liver: a collusion responsible for NIDDM. Diabetes1988, 37:667–687.

    Google Scholar 

  159. Calles-Escandon J, Robbins D: Loss of early phase of insulin release in humans impairs glucose tolerance and blunts thermic effect of glucose. Diabetes1987, 36:1167–1172.

    Google Scholar 

  160. Meyer C, Stumvoll M, Nadkarni V, et al.: Abnormal renal and hepatic glucose metabolism in type 2 diabetes mellitus. J Clin Invest1998, 102:619–624.

    Google Scholar 

  161. Consoli A, Nurjhan N, Capani F, Gerich J: Predominant role of gluconeogenesis in increased hepatic glucose production in NIDDM. Diabetes1989, 38:550–561.

    Google Scholar 

  162. Magnusson I, Rothman D, Katz L, et al.: Increased rate of gluconeogenesis in type II diabetes. A 13C nuclear magnetic resonance study. J Clin Invest1992, 90:1323–1327.

    Google Scholar 

  163. Nurjhan N, Consoli A, Gerich J: Increased lipolysis and its consequences on gluconeogenesis in noninsulin-dependent diabetes mellitus. J Clin Invest1992, 89:169–175.

    Google Scholar 

  164. Kelley D, Mokan M, Veneman T: Impaired postprandial glucose utilization in non-insulin-dependent diabetes mellitus. Metabolism1994, 43:1549–1557.

    Google Scholar 

  165. Roden M, Petersen K, Shulman G: Nuclear magnetic resonance studies of hepatic glucose metabolism in humans. Recent Prog Horm Res2001, 56:219–237.

    Google Scholar 

  166. Turner R: The U.K. Prospective Diabetes Study. A review. Diabetes Care1998, 21(Suppl 3):C35–C38.

    Google Scholar 

  167. Cusi K, DeFronzo R: Metformin: a review of its metabolic effects. Diab Rev1998, 6:89–131.

    Google Scholar 

  168. Stumvoll M, Nurjhan N, Perriello G, et al.: Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med1995, 333:550–554.

    Google Scholar 

  169. Yki-Jarvinen H: Thiazolidinediones. N Engl J Med2004, 351:1106–1118.

    Google Scholar 

  170. Göke B, Herrmann-Rinke C: The evolving role of alpha-glucosidase inhibitors. Diabetes Metab Rev1998, 14:S31–S38.

    Google Scholar 

  171. Hollander PA, Elbein SC, Hirsch IB, et al.: Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study. Diabetes Care1998, 21:1288–1294.

    Google Scholar 

  172. Miles JM, Leiter L, Hollander P, et al.: Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin. Diabetes Care2002, 25:1123–1128.

    Google Scholar 

  173. Amori RE, Lau J, Pittas AG: Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA2007, 298:194–206.

    Google Scholar 

  174. Idris I, Donnelly R: Sodium-glucose co-transporter-2 inhibitors: an emerging new class of oral antidiabetic drug. Diabetes Obes Metab2009, 11:79–88.

    Google Scholar 

  175. Maassen J, Kadowaki T: Maternally inherited diabetes and deafness: a new diabetes subtype. Diabetologia1996, 39:375–382.

    Google Scholar 

  176. Taylor S, Cama S, Accili D, et al.: Mutations in the insulin receptor gene. Endocr Rev1992, 13:566–595.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, School of Medicine and Dentistry, University of Rochester, Rochester, NY, USA

    Mazen Alsahli MD (Endocrine Fellow)

  2. School of Medicine, University of Rochester, Rochester, NY, USA

    John E. Gerich MD (Emeritus Professor of Medicine)

Authors
  1. Mazen Alsahli MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. John E. Gerich MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mazen Alsahli MD .

Editor information

Editors and Affiliations

  1. Division of Endocrinology,, Diabetes & Metabolism, University of Miami, Miami, 33136, Florida, USA

    Jay Skyler

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Alsahli, M., Gerich, J.E. (2012). Pathogenesis of Type 2 Diabetes. In: Skyler, J. (eds) Atlas of Diabetes. Springer, Boston, MA. https://doi.org/10.1007/978-1-4614-1028-7_7

Download citation

  • DOI: https://doi.org/10.1007/978-1-4614-1028-7_7

  • Published:

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4614-1027-0

  • Online ISBN: 978-1-4614-1028-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation